View article

Fibrotic scarring of the retina, termed proliferative vitreoretinopathy (PVR), can cause permanent visual impairment and blindness following corrective surgery for retinal detachment and/or ocular trauma. We have previously shown that multiple intravitreal injections of dasatinib prevent PVR in an animal model. The aim of this research was to develop injectable sustained release systems for dasatinib, which would be preferred for clinical use over multiple ocular injections. To accomplish this, dasatinib was encapsulated in Poly (lactic-co-glycolic acid) [PLGA] particles via a benchtop spray-drying process. Spray drying parameters were optimized using a taguchi statistical approach to obtain particle size between 0.5 and 1.5  μm. Characterization of two different sets of particles, sub-micron and >1.0  μm in average diameter, respectively, showed that dasatinib release from sub-micron particles lasts 15 days while …